In 2018, the Canadian Cancer Trials Group (CCTG) and CRI launched a multi-year collaboration to develop and conduct clinical trials in immunotherapy. The collaboration will leverage comprehensive clinical trial designs like umbrella and basket platforms to more efficiently evaluate emerging therapies, to better adapt to the ever-shifting immuno-oncology landscape, and to speed the delivery of clinical trials. By uniting CRI’s 65 year legacy and expertise in cancer immunology with the cancer research expertise and global footprint at CCTG, the collaboration hopes to accelerate the approval of better treatments for cancer patients around the world.

CCTG is a collaborative network of researchers, physicians, scientists, and statisticians globally recognized for finding the treatments that give people with cancer longer, better quality lives. Created in 1980, the internationally recognized group has conducted over 500 trials in over 40 countries, resulting in major, lifesaving breakthroughs in breast, colorectal, blood, lung, ovarian, brain, and prostate cancer. They are Canada's largest cancer clinical trials cooperative with over 80 member institutions and a network of 2,100 investigators. CCTG develops and conducts clinical trials aimed at improving the treatment and prevention of cancer with the goal of reducing morbidity and mortality from this disease.

The first study under the collaboration is a plasma-based biomarker study:

  • NIMBLe:  Nivolumab and Ipilimumab in Patients with HyperMutated Cancers Detected in BLood (NCT03461952) (Press Release)

View the CRI-CCTG Scientific Leadership Committee.

*Immunotherapy results may vary from patient to patient.